Latest Lamotrigine Stories
WOODCLIFF LAKE, N.J., June 16, 2014 /PRNewswire/ -- Eisai Inc.
WOODCLIFF LAKE, N.J., April 25, 2014 /PRNewswire/ -- Eisai Inc.
FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist WOODCLIFF LAKE, N.J., Jan. 2, 2014 /PRNewswire/ -- Eisai Inc.
New Northwestern Medicine® research offers one of the first in-depth studies of how physiological changes during pregnancy reduce the effects of a commonly used drug to treat bipolar disorder, making women more vulnerable to recurring episodes.
Children whose mothers took antiepileptic drugs (AEDs) while pregnant are at increased risk of early development issues.